Entradas por csanchez

Rev Esp Quimioter 2011:24(4):184-190

Bacteroides mobilizable and conjugative genetic elements: antibiotic resistance among clinical isolates           C. QUESADA-GÓMEZ               The conjugation is one of the most important mechanisms of horizontal gene transfer in prokaryotes, leading to genetic variation within a species and the acquisition of new traits, such as antibiotic resistance. Bacteroides is an obligate anaerobe of the colon and a […]

Rev Esp Quimioter 2011:24(4):175-183

Antimycobacterial natural products – an opportunity for the Colombian biodiversity        J. BUENO, E. D. COY, E. STASHENKO             It is estimated that one-third part of the world population is infected with the tubercle bacillus. While only a small percentage of infected individuals will develop clinical tuberculosis, each year there are approximately eight million new cases and […]

Rev Esp Quimioter 2011:24(3):154-163

Pharmacoeconomic assessment of daptomycin as first-line therapy for bacteraemia and complicated skin and skin structure infections caused by gram-positive pathogens in Spain       S. GRAU, P. REBOLLO, J. CUERVO, S. GIL-PARRADO             Objective: To assess the efficiency of daptomycin as firstline therapy (D) versus daptomycin as salvage therapy after vancomycin (V→D ) or linezolid (L→D) failure in […]

Rev Esp Quimioter 2011:24(3):151-153

Usefulness of monitoring linezolid trough serum concentration in prolonged treatments       R. SOUSA, R. LÓPEZ, J. C. MARTÍNEZ-PASTOR, C. CERVERA, G. BORI, S. GARCÍA-RAMIRO, J. MENSA, A. SORIANO              Linezolid has proven valuable in musculoskeletal infections, however, failure and resistance have been described and toxicity is worrisome when more than 28 days are necessary. We describe […]

Rev Esp Quimioter 2011:24(3):143-150

Economic evaluation of interventions for infectious diseases in Spain: systematic review and comparative analysis       F. CATALÁ-LÓPEZ, A. GARCÍA-ALTÉS, E.  ÁLVAREZ-MARTÍN, R. GÈNOVA-MALERAS, C. MORANT-GINESTAR               Background: There exists the need to evaluate interventions addressed to prevent, control and reduce the burden of the infectious diseases; being economic evaluation an instrument can help to allocate healthcare […]

Rev Esp Quimioter 2011:24(3):136-142

Which is the best empirical treatment in patients with urethritis?       M. A. ORELLANA, M. L. GÓMEZ–LUS               Objective. To know the best empirical treatment of urethritis in patients at the City Center of Madrid. Methods. 2.021 urethral exudates were analyzed in men between January 2003-December 2007. In addition to the traditional cultures, it was determined […]

Rev Esp Quimioter 2011:24(3):131-135

Rapid identification and susceptibility testing of Gram-positive cocci in BacT/ALERT blood cultures by direct inoculation into the Vitek 2 system        A. BARREALES, M. LARA, I. HERNÁNDEZ, Ó. DÍEZ              Introduction: To provide the clinician with early information about blood culture results allows a better prognosis and a reduced mortality rate of the patient with sepsis. […]

Rev Esp Quimioter 2011:24(3):127-130

In vitro activity of retapamulin against linezolid and methicillin–resistant Staphylococcus aureus isolates        F. J. CANDEL, G. MORALES, J. J. PICAZO                Objectives: To determine the in vitro activity of retapamulin and other topical antibiotics (mupirocin, bacitracin, and fusidic acid) usually employed for nasal decolonization, against methicillin-susceptible Staphylococcus aureus (MSSA), methicillin-resistant S. aureus (MRSA), and […]

Rev Esp Quimioter 2011:24(3):123-126

Side effects of benznidazole treatment in a cohort of patients with Chagas disease in non-endemic country     B. CARRILERO, L. MURCIA, L. MARTINEZ-LAGE, M. SEGOVIA              Chagas disease is a disease endemic in Latin America, caused by the parasite Trypanosoma cruzi. Benznidazole is the most commonly used drug for the etiological treatment of the disease although […]

Rev Esp Quimioter 2011:24(3):117-122

Empirical antifungal treatment: a valid alternative for invasive fungal infection   C. VALLEJO, J. BARBERÁN              Empirical antifungal therapy refers to initiation of an antifungal agent at the first possible clinical evidence of fungal infection. It is frequently recommended in neutropenic highrisk hematological patients of invasive fungal infection in order to guarantee an early approach. An […]